Managing Progression After Adjuvant Therapy in Advanced RCC

The conversation transitions to a clinically pressing question: how to manage patients who progress after receiving adjuvant therapy. The panel differentiates between early progression on active therapy versus recurrence after a treatment free interval.

For patients progressing rapidly while on IO based adjuvant therapy, the disease is often biologically aggressive and may require escalation with TKI based strategies. The group discusses the lack of direct data guiding optimal second line choices after adjuvant exposure, particularly with newer agents.

In cases of delayed recurrence, clinicians may consider rebiopsy, assessment of oligometastatic disease, and local therapies such as radiation or surgery when feasible. Disease pace and site of progression significantly inform management. Dangerous sites such as liver or brain metastases prompt more aggressive systemic escalation.

The panel acknowledges that current decisions are often guided by mechanism of action reasoning rather than randomized data in this exact setting. Cabozantinib is discussed as a commonly used and reliable option due to consistent activity in refractory disease. Emerging HIF-2 targeting strategies are also considered, although evidence following prior IO remains evolving.

This segment underscores the challenge of sequencing in the modern era, where adjuvant exposure alters the metastatic landscape. Clinicians must rely on disease tempo, symptom burden, and available mechanistic rationale while awaiting more definitive evidence.